Loic Ysebaert, MD, PhD

Professor of Hematology
IUCT Oncopole, France

Poster(s):

• 1413 - A fixed-duration, chemo-sparing approach in CLL: 8-year results of the phase 2 ICLL-07 FILO trial

• 1416 - CLL18 / MOIRAI: an international phase-III trial aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes in first-line treatment of CLL/SLL

• 1521 - Real-world efficacy and safety of venetoclax +/- rituximab in >75-years old patients or with cardiovascular comorbidities and R/R chronic lymphocytic leukemia: interim results of the VERONE study

• 1704 - Feasibility of an individualized physical activity Intervention in CLL patients receiving ibrutinib +/-venetoclax: preliminary results from the QOLIBRI Study